GALT · Galectin Therapeutics Inc
$3.68
+0.11 (+3.08%)
At close · Aug 21
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern for a period of 12 months from the issuance date of these financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$371.13M
Shares
100.85M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.68
Open$3.62
Day$3.59–3.74
52W close$2.08–6.51
Avg vol 30d472K
Short int8.7M · 8.6% float · 23.6d
Short vol52%
Last earningsAug 14, 2025
DataJan 2020–Aug 2026
Filing10-Q · Aug 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Strong Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+5%
above
Price vs 50-day avg
+0%
above
RSI (14)
55
neutral
MACD trend
Positive
52-week position
36%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+6%
trailing
6-month return
+20%
trailing
YTD return
−12%
this year
Relative strength
+9%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +19 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.62% of float · ▲ +2.4% MoM · 23.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
100 holders — mid 3-yr range
Squeeze score
73
high risk · 0–100
Fundamentals
EPS growth
+37%
Y/Y
Free cash flow
$-23.9M
Balance sheet
$17.7M
net cash
Quant / Vol
risk profile
Volatility
95%
annualized · 1-yr
Max drawdown
−68%
past year
ATR
8.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+5%
Bullish
Price vs 50-day avg
+0%
Bullish
RSI (14)
55
Neutral
MACD trend
Positive
Bullish
52-week position
36%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
Golden cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +19 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.62% of float · ▲ +2.4% MoM · 23.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
100 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $4 · 36%
Range high $7
vs 200-day avg +5%
vs 50-day avg +0%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GALT
this stock
Galectin Therapeutics Inc
|
$371.13M | -11.5% | — | — | 8.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GALT | +7.0% | +6.1% | +20.3% | +23.9% | -11.5% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +8.4% | +2.4% | +8.7% | +21.4% | -23.8% |
Key facts
CIK
1133416
CUSIP
363225202
13F (30d)
95 filings
93 filers
Visit website
Investor relations